Trial Profile

A Phase 2 trial of R327 for the treatment of UTIs

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 02 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RECCE 327 (Primary)
Indications Urinary tract infections
Focus Therapeutic Use
Sponsors Recce Pharmaceuticals

Most Recent Events

01 Jul 2024 According to a Recce Pharmaceuticals media release, the company is on track to initiate Phase II trial of R327 in patients with urinary tract infections in H2 2024
07 Oct 2022 New trial record
03 Oct 2022 According to a Recce Pharmaceuticals media release, the first patient in the study expected to be dosed in early 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com